Consistent use for 812 weeks is recommended
With them, its not just about the number on the scale
And so supplementation may become advantageous at that point
In 2023, Pfizer published research papers successively, reporting the results of randomized clinical trials on the efficacy and safety of PF-06882961 for blood sugar control in patients with type 2 diabetes, the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06882961 in Japanese adults with type 2 diabetes from a phase 1 clinical trial, and the results of a 12-week randomized, placebo-controlled, dose-escalation phase 2 trial on the tolerability, safety, and pharmacodynamics of PF-06882961 for the treatment of type 2 diabetes
According to Markets and Markets, the global GLP-1 agonists market, valued at $53.74 billion in 2024, rose to $64.42 billion in 2025 and is projected to reach $170.75 billion by 2033